shares of biopharmaceutical company ymabs therapeutics inc climbed tuesday a day after the company reported firstquarter revenue rising from the yearago period at 128 pm et the stock increased 2056 to 991 per share after the bell monday the company reported a firstquarter loss per share of 64 cents on revenue of 105 million in the yearago period ymabs reported firstquarter earnings per share of 80 cents on revenue of 538 million the decrease in earnings was primarily driven by a onetime 62 million net gain from the sale of our danyelza priority review voucher in the quarter ended march 31 2021 partially offset by the favorable impact of increasing danyelza revenues ymabs said the company said danyelza is used in combination to treat patients with highrisk neuroblastoma in the bone or bone marrow the company on monday said it was expecting 2022 fullyear danyelza revenue in a range between 45 million and 50 million ymabs also said it had a cash position with 1567 million as of march 31 providing runway through mid2024